Alogliptin

證據等級: L5

預測適應症: 10 個

Alogliptin: From Type 2 Diabetes to Classic Stiff Person Syndrome

One-Sentence Summary

Alogliptin is a selective DPP-4 (dipeptidyl peptidase-4) inhibitor, approved internationally for the treatment of type 2 diabetes mellitus (T2DM) by enhancing incretin-mediated insulin secretion. The TxGNN model predicts it may be effective for Classic Stiff Person Syndrome (SPS) — a rare autoimmune neurological disorder — based on DPP-4’s immunomodulatory role in T-cell regulation. However, this prediction is currently supported by 0 clinical trials and 0 publications specifically addressing this indication, making it a purely model-driven hypothesis at this stage.

Quick Overview

Item	Content
Original Indication	Type 2 Diabetes Mellitus (based on international pharmacological data; no Taiwan (TFDA) approval record available)
Predicted New Indication	Classic Stiff Person Syndrome
TxGNN Prediction Score	98.01%
Evidence Level	L5
Taiwan Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological information, Alogliptin belongs to the DPP-4 inhibitor class (gliptins). Its therapeutic mechanism in T2DM involves selective inhibition of dipeptidyl peptidase-4, thereby prolonging the activity of incretin hormones GLP-1 and GIP — stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon release. Critically, DPP-4 is also known as the surface marker CD26, which is highly expressed on activated T lymphocytes.

Classic stiff person syndrome (SPS) is a rare, debilitating autoimmune neurological disease primarily driven by antibodies against glutamic acid decarboxylase 65 (anti-GAD65). The anti-GAD65 autoimmune attack impairs GABA synthesis in inhibitory interneurons of the spinal cord, leading to progressive muscle rigidity and spasms. Since DPP-4/CD26 plays a functional role in T-cell activation and the Th1/Th2 immune balance, DPP-4 inhibition theoretically carries immunomodulatory potential that could dampen autoimmune activity underlying SPS.

However, this mechanistic link is highly indirect. The pathway from systemic DPP-4 inhibition to meaningful attenuation of anti-GAD65-mediated neurological autoimmunity has not been demonstrated in any preclinical model or clinical observation. The TxGNN score reflects a graph-based structural relationship in the knowledge graph rather than experimentally validated biology. At present, this prediction should be treated as a hypothesis-generating signal only.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for the Classic Stiff Person Syndrome indication specifically.

Note: 3 publications were retrieved for the separately ranked Pancreatic Agenesis indication (Rank #6). These are not directly relevant to the top-ranked SPS indication but are listed below for reference, as they describe Alogliptin’s β-cell protective mechanisms.

PMID	Year	Type	Journal	Key Findings
20859539	2010	Review/Commentary	Vascular Health and Risk Management	Discusses pioglitazone + alogliptin combination rationale in T2DM; highlights alogliptin’s role in addressing GLP-1 deficiency and β-cell dysfunction
21205126	2011	Animal Study / Preclinical	Diabetes, Obesity & Metabolism	Chronic alogliptin administration improved glucose control and preserved pancreatic islet function in a high-fat diet / streptozotocin mouse T2DM model
22071236	2011	Review	Clinical Therapeutics	Review of DPP-4 inhibitor tolerability in T2DM; covers monotherapy and combination therapy safety profiles across the gliptin class

Taiwan Market Information

Alogliptin currently holds no TFDA marketing authorization in Taiwan. No approved indications, dosage forms, or license records are available in the Taiwan regulatory database.

Safety Considerations

Please refer to the SmPC (Summary of Product Characteristics) or the official prescribing information for safety details. Taiwan-specific label warnings and contraindications were not available in this Evidence Pack (Data Gap: TFDA 仿單 not retrieved). No drug-drug interaction data was returned from the DDI query.

Conclusion and Next Steps

Decision: Hold

Rationale: All 10 predicted indications in this Evidence Pack are classified at Evidence Level L5 — meaning the predictions are generated solely by the TxGNN model with no supporting clinical trials or disease-specific literature. The top-ranked indication (Classic Stiff Person Syndrome) has a plausible but highly indirect mechanistic hypothesis and zero empirical support; proceeding to any translational or regulatory activity is premature.

To proceed, the following is needed:

Retrieve MOA data: Query DrugBank API for Alogliptin (DB06203) to formally document the mechanism of action and enable rigorous mechanistic-link analysis
Retrieve TFDA prescribing information: Download and parse the TFDA SmPC PDF to populate key warnings, contraindications, and special population data (Data Gap DG001 — currently Blocking)
Preclinical evidence scan: Conduct a broader PubMed search using MeSH terms combining “DPP-4 inhibitor” OR “gliptin” with “stiff person syndrome” OR “autoimmune neurological disease” to determine if any class-level (non-alogliptin) evidence exists
Class-level evidence review: Evaluate whether sitagliptin or other DPP-4 inhibitors have published data in autoimmune disease models, as class effects may partially inform the plausibility of this prediction
Indication prioritisation review: Given that 9 of 10 predicted indications are orphan/rare diseases with no evidence, consider whether mechanistically better-supported indications (e.g., Thiamine-Responsive Dysfunction Syndrome, which shares β-cell biology) warrant higher priority for evidence collection
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.